Table 2. Incidence of Venous Thromboembolism Among Individuals With IMIDs and Matched Controls Within 6 Months and 12 Months of COVID-19 Diagnosis.
| IMID | People with an IMID | Matched people without an IMID | ||
|---|---|---|---|---|
| Crude IR per 100 000 PD (95% CI) | Standardized IR per 100 000 PD (95% CI) | Crude IR per 100 000 PD (95% CI) | Standardized IR per 100 000 PD (95% CI) | |
| Events within 6 mo of COVID-19 diagnosis | ||||
| Any IMID | 3.72 (3.17-4.35) | 2.64 (2.23-3.10) | 2.77 (2.54-3.02) | 2.18 (1.99-2.38) |
| Ankylosing spondylitis | 2.72 (1.00-5.93) | 2.34 (0.81-5.27) | 3.38 (2.34-4.72) | 2.84 (1.88-4.10) |
| Inflammatory bowel disease | 1.84 (0.95-3.21) | 1.70 (0.78-3.21) | 2.21 (1.71-2.81) | 2.17 (1.58-2.91) |
| Crohn disease | 2.86 (1.23-5.63) | 3.54 (0.99-8.96) | 1.94 (1.25-2.86) | 2.69 (1.24-5.08) |
| Ulcerative colitis | 1.16 (0.32-2.98) | 0.79 (0.21-2.04) | 2.55 (1.82-3.47) | 2.20 (1.46-3.19) |
| Multiple sclerosis | 3.03 (1.38-5.75) | 3.03 (1.06-6.77) | 2.14 (1.43-3.07) | 1.77 (1.12-2.67) |
| Psoriasis | 2.93 (2.16-3.88) | 2.24 (1.63-3.00) | 2.94 (2.57-3.36) | 2.24 (1.94-2.58) |
| Psoriatic arthritis | 4.06 (1.63-8.36) | 5.71 (2.57-10.96) | 2.19 (1.28-3.51) | 1.29 (0.74-2.10) |
| Polymyalgia rheumatica | 6.48 (2.10-15.12) | 1.13 (0.26-3.14) | 3.94 (1.97-7.06) | 0.85 (0.36-1.68) |
| Rheumatoid arthritis | 6.47 (4.91-8.36) | 2.89 (0.91-6.85) | 3.29 (2.75-3.92) | 2.20 (1.76-2.71) |
| Systemic autoimmune rheumatic disease | 6.06 (3.84-9.10) | 6.73 (3.13-12.62) | 2.07 (1.45-2.86) | 1.75 (1.05-2.74) |
| Uveitis | 4.20 (2.53-6.56) | 2.91 (1.65-4.75) | 2.97 (2.25-3.84) | 1.78 (1.34-2.33) |
| Events within 12 mo of COVID-19 diagnosis | ||||
| Any IMID | 2.60 (2.24-2.99) | 1.82 (1.56-2.11) | 1.79 (1.65-1.94) | 1.37 (1.25-1.49) |
| Ankylosing spondylitis | 2.14 (0.92-4.21) | 1.79 (0.71-3.70) | 2.03 (1.41-2.82) | 1.66 (1.11-2.38) |
| Inflammatory bowel disease | 1.56 (0.91-2.50) | 1.48 (0.80-2.50) | 1.47 (1.16-1.85) | 1.43 (1.06-1.89) |
| Crohn disease | 2.19 (1.05-4.02) | 2.56 (0.82-6.02) | 1.36 (0.91-1.96) | 1.95 (0.87-3.74) |
| Ulcerative colitis | 1.21 (0.48-2.48) | 0.99 (0.38-2.10) | 1.65 (1.20-2.22) | 1.42 (0.96-2.02) |
| Multiple sclerosis | 2.57 (1.37-4.39) | 2.96 (1.22-6.00) | 1.42 (0.98-1.99) | 1.13 (0.74-1.66) |
| Psoriasis | 2.17 (1.66-2.79) | 1.61 (1.21-2.09) | 1.91 (1.68-2.17) | 1.41 (1.23-1.61) |
| Psoriatic arthritis | 3.06 (1.40-5.81) | 4.33 (1.47-9.84) | 1.50 (0.92-2.32) | 1.02 (0.59-1.64) |
| Polymyalgia rheumatica | 5.07 (2.04-10.45) | 4.29 (0.38-17.19) | 2.38 (1.23-4.15) | 0.53 (0.24-1.01) |
| Rheumatoid arthritis | 4.06 (3.13-5.18) | 2.02 (0.80-4.21) | 2.09 (1.76-2.46) | 1.37 (1.11-1.67) |
| Systemic autoimmune rheumatic disease | 3.66 (2.35-5.45) | 4.10 (1.82-7.92) | 1.38 (1.00-1.87) | 1.16 (0.73-1.75) |
| Uveitis | 2.80 (1.75-4.23) | 1.90 (1.12-3.01) | 1.96 (1.52-2.48) | 1.11 (0.85-1.43) |
Abbreviations: IMID, immune-mediated inflammatory disease; IR, incidence rate; PD, person-days.